Interaction of a doxorubicin-transferrin conjugate with isolated transferrin receptors

doi:10.1016/0024-3205(94)00575-3

Life Sciences

Volume 54, Issue 1, 1994, Pages 35-40

https://doi.org/10.1016/0024-3205(94)00575-3 Get rights and content

Abstract

It is shown that transferrin-doxorubicin conjugates bind to isolated transferrin receptors. The receptors were isolated from human full-term placenta by solubilization of trophoblast plasma membranes with the nonionic detergent C₁₂E₈ and then by affinity chromatography on a diferric transferrin-coupled Sepharose CL-4B column. The binding affinity of such conjugate was similar to that of transferrin. Dissociation of conjugate from the isolated receptor occurred with time-dependent kinetics similar to those of transferrin when the experimental conditions mimicking the physiological steps of transferrin recycling were consecutively applied. These results support the idea that a) binding of such conjugates is primarily governed by the interaction between the transferrin part of the conjugates and the transferrin receptor, and b) it is not the transferrin receptor itself which participates in the putative secondary interaction between the receptor-bound conjugates and plasma membrane.

References (27)

S. Avrameas
Immunochemistry
(1969)
C.-J.G. Yeh et al.
Clin. Immunol. Immunopathol.
(1984)
A. Berczi et al.
Arch. Biochem. Biophys.
(1993)
P.J. Fraker et al.
Biochem. Biophys. Res. Commun.
(1978)
B. Khalfoun et al.
FEBS-Letters
(1985)
G.J. Anderson et al.
Biochim. Biophys. Acta
(1986)
J.R. Rudolph et al.
J. Chromatogr.
(1987)
D.M. Sipe et al.
J. Biol. Chem.
(1991)
T.R. Tritton
Pharmac. Ther.
(1991)
K. Barabas et al.
J. Biol. Chem.
(1992)

C. Schneider et al.

J. Biol. Chem.

(1982)

W.P. Faulk et al.

M. Fritzer et al.

Int. J. Cancer

(1992)

Cited by (8)

The plasma membrane NADH-diaphorase is active during selective phases of the cell cycle in mouse neuroblastoma cell line NB41A3. Its relation to cell growth and differentiation
1996, Biochimica et Biophysica Acta - Molecular Cell Research
Plasma membrane oxidoreductases have been described in all cells and use extracellular impermeant electron acceptors (DCIP, Ferricyanide) that are reduced by NADH. They appear to regulate the overall cell activity in response to oxidative stress from the cellular environment. An NADH-DCIP reductase has been described at the plasma membrane of NB41A3, a neuroblastoma cell line (Zurbriggen and Dreyer (1993) Biochim. Biophys. Acta 1183, 513–520) whose activation with extracellular impermeant substrates promotes cell growth. Elutriation was performed to separate cells and the various fractions were analysed for enzyme activity on intact cells combined with flow cytometry. These studies showed that the enzyme is mostly induced and activated during the G1 and during the G2/M-phases. These observations were further corroborated with specific inhibitors of the cell cycle. A three-fold increase in enzyme activity was observed in the presence of α-amanitin, a specific cell cycle inhibitor of the G1-phase. Taxol, a specific inhibitor of the M-phase, also induces a significant increase in enzyme activity. FACS analysis of taxol-treated and α-amanitin-treated cells corroborated these data. The cells have been synchronized and the enzyme activity was measured at different time intervals. An activity increase was observed after ca. 2–3 h, that corresponds to a raise in the M-phase, according to FACS data. Furthermore, NTera-2 cells — a human neuroblastoma cell line that differentiates into fully mature neurones in the presence of retinoic acid — exhibit a 50% decrease in the enzyme activity during the G0-phase upon differentiation, compared to undifferentiated cells. Together the data presented in this paper show that this plasma membrane NADH-diaphorase affects cell growth and differentiation and is strongly modulated at various phases of the cell cycle.
Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells
1996, Biochemical Pharmacology
Cancer chemotherapy is often limited by the emergence of multidrug-resistant tumor cells. Multidrug resistance (MDR) can be caused by amplification of the MDR genes and overexpression of the P-glycoprotein, which is capable of lowering intracellular drug concentrations. A doxorubicin-transferrin conjugate has been synthesized and exerts its cytotoxic effects through a transmembrane mechanism. We have examined the cytotoxicity of this conjugate and compared it with doxorubicin in sensitive (KB-3-1) and in multidrug-resistant KB cell lines (KB-8-5, KB-C1, and KB-V1). In the clonogenic assay, doxorubicin exhibited IC₅₀ concentrations of 0.03 and 0.12 μM in the sensitive (KB-3-1) and resistant (KB-8-5) cell lines, respectively, whereas, doxorubicin-transferrin conjugate was more effective with IC₅₀ concentrations of 0.006 and 0.028 μM, respectively. In highly multidrug-resistant KB-C1 and KB-V1 cells, doxorubicin up to 1 μM did not cause any cytotoxic effects, while the doxorubicin-transferrin conjugate inhibited colony formation of these cells with IC₅₀ levels of 0.2 and 0.025 μM, respectively. These results demonstrate that doxorubicin-transferrin is effective against multidrug-resistant tumor cells.
Prodrugs of anthracyclines in cancer chemotherapy
2006, Current Medicinal Chemistry
Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention
2005, Molecular Pharmaceutics
Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway
2002, Pharmacological Reviews
Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: Evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells
2000, Anticancer Research

View all citing articles on Scopus

View full text

Interaction of a doxorubicin-transferrin conjugate with isolated transferrin receptors

Abstract

Immunochemistry

Clin. Immunol. Immunopathol.

Arch. Biochem. Biophys.

Biochem. Biophys. Res. Commun.

FEBS-Letters

Biochim. Biophys. Acta

J. Chromatogr.

J. Biol. Chem.

Pharmac. Ther.

J. Biol. Chem.

J. Biol. Chem.

Int. J. Cancer